文献速递抗栓抗凝管理肝肾功能剂量调整治疗药物监测与药物基因组学

达比加群酯实验室监测成功指导侵入性操作时机

Successful use of laboratory monitoring to facilitate an invasive procedure for a patient treated with dabigatran.
PubMed 文献 · Am J Health Syst Pharm · 2017-02-10

一例86岁女性房颤患者服用达比加群酯期间发生右股骨颈骨折需手术,临床药师团队建议延迟手术至末次给药后3-5天,并以蛇静脉酶显色测定(ECA)达比加群浓度<50 ng/mL作为术前目标。住院期间联合监测ECA、活化部分凝血活酶时间、凝血酶时间和凝血酶原时间,最终在末次给药5天后行手术。

要点

  • 达比加群酯停药后清除约需3-5天,术前建议ECA浓度<50 ng/mL。
  • 肾功能不全会延迟达比加群酯消除,需加强凝血监测。
  • ECA、APTT、TT和PT可联合用于评估达比加群酯残留抗凝效应。

核心结论

  • 对服用达比加群酯的老年患者行非紧急手术前,采用以ECA浓度<50 ng/mL为重点的凝血监测可评估出血风险。

研究设计与样本

  • 单例病例报告:86岁女性房颤患者因右股骨颈骨折需手术,住院期间监测达比加群酯相关凝血指标。

主要发现

  • 临床药师团队建议延迟手术,因达比加群酯清除约需3-5天,术前ECA达比加群值<50 ng/mL为宜。
  • 住院期间监测ECA值、活化部分凝血活酶时间、凝血酶时间和凝血酶原时间以确定最佳手术时机。
  • 肾功能不全可能延迟达比加群酯消除并导致潜在蓄积,患者最终在末次给药5天后行手术。

关键数值与推荐

  • 术前ECA达比加群浓度目标为<50 ng/mL。
  • 达比加群酯清除预计需3-5天。
  • 患者实际等待末次达比加群酯给药后5天行手术。

临床怎么用

  • 对服用达比加群酯需非紧急手术者,可咨询临床药师团队制定停药与监测计划。
  • 联合ECA、APTT、TT和PT评估达比加群酯残留效应,以ECA浓度<50 ng/mL作为术前参考。
  • 肾功能不全患者应预期达比加群酯消除延迟,需延长监测和等待时间。

局限性

  • 单例病例报告,结论外推需谨慎。
  • 未报告ECA、APTT、TT、PT的具体数值及肾功能指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A case in which novel and traditional laboratory markers were successfully used to determine surgical intervention timing in an elderly patient receiving dabigatran for atrial fibrillation is reported. SUMMARY: An 86-year-old woman who was taking dabigatran for atrial fibrillation suffered a right femoral neck fracture requiring surgical intervention. Dabigatran was withheld once the patient was admitted to the hospital, and the pharmacy inpatient anticoagulation management team was consulted for guidance on determining appropriate scheduling of surgical intervention with regard to the time since her most recent dabigatran dose to minimize bleeding complications. The team recommended delaying surgery, as dabigatran clearance would likely take 3-5 days and an ecarin chromogenic assay (ECA) dabigatran value of <50 ng/mL would be desirable before surgical intervention. During her hospitalization, novel and traditional laboratory markers for dabigatran, such as ECA value, activated partial thromboplastin time, thrombin time, and prothrombin time, were measured and followed closely to determine the best time to perform surgical intervention to minimize bleeding risk. Renal dysfunction likely delayed dabigatran elimination in the patient and may have led to potential accumulation of dabigatran. The patient ultimately had to wait 5 days after the last dabigatran dose for surgical intervention. CONCLUSION: Coagulation assay monitoring for dabigatran, with emphasis on an ECA dabigatran concentration of <50 ng/mL, was used to assess safety regarding bleeding risk before a nonemergent surgical procedure in an 86-year-old woman with a right femoral neck fracture.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Byron M, Zochert S, Hellwig T, et al. Successful use of laboratory monitoring to facilitate an invasive procedure for a patient treated with dabigatran. Am J Health Syst Pharm. 2017. PMID: 28188221. doi:10.2146/ajhp160168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。